Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) and Savara (NASDAQ:SVRA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.
Risk & Volatility
Unicycive Therapeutics has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.
Institutional and Insider Ownership
40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Unicycive Therapeutics | $680,000.00 | 312.74 | -$26.56 million | ($2.17) | -3.67 |
| Savara | N/A | N/A | -$118.84 million | ($0.53) | -9.73 |
Unicycive Therapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings for Unicycive Therapeutics and Savara, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Unicycive Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
| Savara | 1 | 1 | 6 | 1 | 2.78 |
Unicycive Therapeutics presently has a consensus target price of $24.75, suggesting a potential upside of 210.73%. Savara has a consensus target price of $9.13, suggesting a potential upside of 77.01%. Given Unicycive Therapeutics’ higher possible upside, equities research analysts plainly believe Unicycive Therapeutics is more favorable than Savara.
Profitability
This table compares Unicycive Therapeutics and Savara’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Unicycive Therapeutics | N/A | -144.30% | -87.28% |
| Savara | N/A | -84.01% | -63.60% |
Summary
Savara beats Unicycive Therapeutics on 7 of the 13 factors compared between the two stocks.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
About Savara
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
